A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan
Phase of Trial: Phase IV
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 06 Mar 2018 Status changed from active, no longer recruiting to completed.
- 14 Feb 2018 Status changed to active, no longer recruiting.
- 19 Jan 2018 Planned end date changed from 29 Dec 2017 to 31 Jan 2018.